AfterRaise/Companies/Infinimmune

Infinimmune

Infinimmune is a biotechnology company developing antibody therapeutics derived directly from the human immune system. From its funding announcement.

$75M Series ARaised 2 months agoAlameda, USABiotech & PharmaUSA
Visit website →

In their own words

What Infinimmune says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotechnology company developing antibody therapeutics derived directly from the human immune system". Source

ProductResearch and developmentInfrastructure

Public signal Read from the company's own description of what the funding supports.

Why now

Where Infinimmune is today

Infinimmune announced a Series A round of $75M on 12 August 2026, led by Regeneron Ventures and Playground Global.

Latest round
Series A
Amount
$75M
Announced
12 August 2026
Headquarters
Alameda, USA
Sector
Biotech & Pharma
Investors
Also participating
RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures, Pear VC
Relevant leadership
Co-Founder and CEO Wyatt McDonnell

Momentum AfterRaise intelligence

AfterRaise Score

62
Building momentum
1 funding signal in the last 90 days
Funding recency
28/40
announced within the last 90 days
Round scale
19/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 12 August 2026
    $75M Series A
    Led by Regeneron Ventures and Playground Global.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Product leadership
  • Design partners

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Medium momentum4 connected signals
  • 12 August 2026$75M Series A announced
  • 12 August 2026Stated priority: product
  • 12 August 2026Stated priority: research and development
  • 12 August 2026Stated priority: infrastructure

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Infinimmune is open to

Not yet specified

Infinimmune has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Infinimmune

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Infinimmune?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector